Third Brazilian Consensus for autoantibodies screening in HEp-2 cells (ANA).

Recommendations for standardization of autoantibodies screening trial in HEp-2 cells, quality control and clinical associations

Alessandra Dellavance(1), Alexandre Gabriel Júnior(2), Barbara Nuccitelli(3), Ben Hur Taliberti(4), Carlos Alberto von Mühlen(5), Carlos David Araújo Bichara(6), Cláudio Henrique Ramos dos Santos(7), Cleonice Bueno(8), Cristiane Martinez Yano(9), Cristóvão Luís Pitangueria Mangeira(10), Darlene Gonçalves Carvalho(11), Elizângela Cardoso(12), Eloísa Bonfá(13), Flávia Ikeda e Araújo(14), Gustavo Gabriel Rassi(15), Hugo Mendonça Mundim(16), Izidro Bender(17), Jozélia Rego(18), Lisiane Maria Enriconi dos Anjos Vieira(19), Luís Eduardo Coelho Andrade(20), Maria Ordália Ferro Barbosa(21), Mitiko Sugiyama(22), Mittermayer Barreto Santiago(23), Natasha Shlessarenko(24), Nílzião Antônio da Silva(25), Paula Luiz Carvalho Francescanionio(26), Renata Jarach(27), Roberto Suda(28), Roger Abramino Levy(29), Silvia Oliveira Sampaio(30), Suzane Pretti Figueiredo Neves(31), Wilson de Melo Cruvinel(32), Wilton Silva dos Santos(33), Yanna K. de M. Nóbrega(34)
Objective: The Third Brazilian Consensus for autoantibodies Screening in HEp-2 cells had as purpose the evaluation of difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, the discussion of strategies for quality control of the assay and the promotion of an update of the clinical associations of the several immunofluorescent patterns. Methods: Several ANA experts from university centers and private laboratories in different areas in Brazil joined the workshop in Goiânia on 2008 April 13 and 14 with the purpose of discussing and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial representatives of different ANA slide brands were also invited as listeners to the workshop. Results and Conclusions: The 3rd Consensus emphasized the need for quality control in indirect immunofluorescent since there is a considerable heterogeneity of available microscopes and reagents. It also promoted adaptations in the previously approved terminology used to classify the different patterns and finally updated the clinical associations of the several patterns with the purpose of providing guidance for interpretation of the assay by clinical pathologists and assistant physicians.

Keywords: autoantibodies, HEp-2 cells, Antinuclear antibodies, Immunofluorescent.

INTRODUCTION

Historic outlook of autoantibodies screening using HEp-2 in Brazil

Technological and scientific development has promoted changes in laboratory tests that affect important parameters for clinical interpretation, such as positive and negative predictive values, sensitivity and specificity. An excellent example of this situation is the antinuclear antibody (ANA) screening using the indirect immunofluorescent (IIF) technique, also known as antinuclear factor, today called “screening for antibody against cell antigens” in serum of patients under autoimmune disease suspicion. It is an excellent test to track autoantibodies that, along the last decades, has been technically changed to provide a progressively higher sensitivity. As a consequence, the antibody screening against cell antigens also started to present lower specificity.¹

However, the increment of ANA-IIF test sensitivity using HEp-2 cells also brought up a loss in specificity, as some individuals without clinical or laboratory evidence of autoimmune disease also presented positive results in HEp-2 cells, requiring a strict interpretation of serological findings.² The high frequency of positive results in healthy individuals or...
individuals with vague clinical manifestations has revealed a situation called “syndrome of idiopathic antinuclear antibody”. Loss of specificity in this test has also been aggravated due to the fact that a wide range of expert physicians started to use it. Initially, rheumatologists and nephrologists were the main users of this exam and, due to a familiarity with it and their patients’ characteristics, they had more chances to request this test for those who really had an autoimmune history.

Today, ANA-IIF using HEp-2 is a test requested with fewer criteria by a wide range of specialists, who obviously see to different patients, in which autoimmune rheumatic disease diagnosis is less prevalent. Thus, the chance of positive results in healthy individuals, or with low expressive clinical presentations, became higher. Some elements are important to suitable value the ANA-IIF in HEp-2 test. Firstly, this test should be requested only under convincing suspicion of autoimmune disease. Requesting this test for a patient presenting uncertain complaints frequently will bring more confusion to the clinical judgment, as a positive result does not necessary mean autoimmunity. A second point to be considered is ANA-IIF in HEp-2 titer: in general, autoimmune patients tend to present moderate (1/160 and 1/320) and high (≥ 1/640) titers, while healthy individuals tend to present low titers (1/80). However, both situations may present exceptions. Another important point is the fluorescence pattern that shows the identity of autoantibody(ies) in consideration; it should be carefully analyzed taking in account the experience and expertise of observer, as well as the capacity to reproduce the pattern using kits by different manufacturers.

Autoantibodies against some antigens have specific association with certain autoimmune diseases or to autoimmunity state while others occur indiscriminately in autoimmune and non-autoimmune individuals. So, certain fluorescence patterns are more specific to autoimmune disease while others happen frequently in healthy individuals or in patients with other non-autoimmune diseases.

Another point to be considered is that the physiological autoimmunity level, or basal level, may fluctuate depending on the overcharges the immune system is exposed to. The autoantibody presence broken out by infections, drugs or neoplasia is well demonstrated. High prevalence of autoantibodies in patients with HIV (human immunodeficiency virus) and other lymphotropic virus has been clearly demonstrated. Therefore, an important point to take into consideration when evaluating a positive finding of ANA-IIF using HEp-2 cells refers to the possibility of recent viral infections, drug use and neoplastic processes.

Several evidences demonstrate that autoantibodies frequently precede clinical diagnosis of autoimmune diseases. A positive ANA-IIF using HEp-2 test may precede clinical systemic lupus erythematosus (SLE) in up to nine years. Almost 80% of patients with SLE present positive ANA-IIF in HEp-2 before the first symptoms. Although in a lower percentage, it is also valid for several autoantibodies specific for this disease, such as double stranded anti-DNA and anti-Sm. Consequently, another possibility to be considered facing a clinically inconsistent finding of positive ANA-IIF in HEp-2 is that the patient may develop an autoimmune disease in the future years. However, some individuals may continue for decades with circulating autoantibodies without developing any signal of autoimmune disease.

It is essential to better characterize a positive ANA-IIF in HEp-2 cell by searching for hallmark antibodies proper to autoimmune pathologies by specific techniques. This evaluation should be supported by clinical or laboratorial evidence of a systemic autoimmune disease. Additionally to clinical examination, it is important to check possible changes in blood count, urine, C-reactive protein and erythrocyte sedimentation rate (vHS), which may be considered extensions of the clinical exam. In some cases, analyzing hepatic and muscular enzymes may be valid. Vague symptoms, like arthralgias and asthenia, with normal general laboratory tests are not sufficient to provide support for a laboratorial finding of ANA-IIF in HEp-2 in low titer and with low specific fluorescence pattern. In such cases, common sense and follow-up of the patients with regular visits may be the best decision.

The first two Consensuses contributed to improve readings and interpretation of ANA-IIF using HEp-2 patterns by the definition of morphological criteria to be followed during the reading of test, and by the establishment of a combination criteria including the main groups (nucleus, nucleolus, cytoplasm, mitotic apparatus and mixed). Information on main clinical associations of different patterns was approached and a new terminology was suggested so that the test would express its diagnostic dimension.

After the second Consensus, some questions arose requiring more discussion and better orientation. One of the problems observed concerns the classification of homogeneous nuclear pattern regarding the nucleolus reactivity and the mixed pattern classification, approaching multiple reactivities in the same group, e.g., a pattern with two or more autoantibodies against nuclear antigens. Another relevant aspect was the need to advice about substract heterogeneity, beginning with conjugate titer. Since some laboratories are not familiarized with titering the conjugate against an absolute or consensual pattern, the
same test carried out in kits by different brands may present different titers. These problems, as a whole, are responsible for heterogeneity in results among several laboratories and should be deeply discussed.

Finally, along these two years, there was a need to review clinical associations of different patterns established in the 2nd Consensus. Thus, the Third Brazilian Consensus for autoantibodies Screening in HEp-2 Cells (ANA) intended to evaluate the difficulties in the accomplishment of the 2nd Consensus recommendations that took place in the year of 2002, to discuss strategies for quality control of the assay and to promote an update for the clinical associations of the several immunofluorescent patterns.

**METHOD OF WORK**

Several ANA experts from university centers and private laboratories from different areas in Brazil joined the workshop in Goiânia on April 13 and 14, 2008, with the purpose of discussing and approving the recommendations for standardization, interpretation and use of the test by physicians. Commercial representatives of different ANA slide brands were also invited as listeners to ANA-IIF in HEp-2 test.

The group approached problems like the need for test quality control, definition of some controversial aspects in the classification proposed in the 2nd Consensus, report of new fluorescence patterns and review of clinical associations. These problems were presented to members and widely discussed in order to get a consensus among several participants. Discussions were based on previous review of the literature concerning different subjects, as well as presentation of their own data.

**GENERAL RECOMMENDATION**

Nucleolus classification according to homogeneous nuclear pattern becomes negative

The 3rd Consensus reaffirms the current classification of fluorescence patterns in four cell structures (cytoplasm, nucleus, nucleolus and mitotic apparatus). Additionally, some definitions were done for some possible ambiguous or vague situations. In cases where nucleus is uniformly stained and nucleolus region is not highlighted, the Consensus members understand that there is no essential reactivity against nucleolus; therefore, it should be described as “negative”. Obviously, nucleolus will also be described as “negative” in cases where it is not stained. When there is a nuclear pattern, nucleolus will only be described as “positive” when its stain becomes visible over the nucleus stain. The example below showing homogeneous nuclear pattern report is recorded:

- **Patient**: F.C.O.F.
- **Assay**: antibody screening against cell antigens (ANA)
- **Nucleus**: Positive.
- **Nucleolus**: Negative.
- **Cytoplasm**: Negative.
- **Mitotic apparatus**: Negative.
- **Chromosomal metaphase plate**: Positive
- **Pattern**: Homogeneous nuclear

**Mixed patterns**

Mixed Patterns definition was corrected. Every case where different staining for cellular structures (nucleus, nucleolus, cytoplasm or mitotic apparatus) or different fluorescence patterns in one cell structure was classified as mixed pattern. Thus, for example, NuMA-1 pattern is considered a mixed pattern, because the nucleus and mitotic apparatus are stained. Another example is represented by a serum with an autoantibody mixture that simultaneously stain the nucleus with a fine speckled pattern and centromere speckled pattern.

**Speckled nuclear pattern with separate dots**

The 3rd Consensus changed the decision of the 2nd Consensus about the need for subclassification of the number of dots in speckled nuclear pattern with isolate dots in >10 and <10. Pattern terminology has been established as speckled with isolated dots. This change happens because the number of nuclear stained bodies by anti-p80-coilin and anti-sp-100 antibodies varies according cell substrate in use. Although, in most cases, expert observer may safely suggest the most probable autoantibody, the number of dots per nucleus is not an absolute criterion.

**Non-characterized patterns or patterns with new features**

Consensus members acknowledge that there are non-characterized patterns or patterns with no defined characteristics in the existing classification. In these cases, recommendation is to describe morphologically the pattern observed and to add a note specifying that it is not part of the Consensus terminology and that its immunologic and clinical associations have not been defined yet. In such cases, it is essential that the laboratory tests this new proposed pattern in commercial kit under a different brand than the one where the pattern was originally
observed, avoiding human conditions that could result a false interpretation.

Two new fluorescence patterns were communicated by few Consensus members. Many other members declared they had already observed such patterns.

The first one is a nuclear fine speckled immunofluorescent pattern, with an almost homogeneous texture and with homogeneously stained metaphase plate. Its clinical association and immunological identity are not defined. Its importance comes from the fact that it may be easily confused with a dense fine speckled pattern and a homogeneous pattern (Figure 1).

The second is a cytoplasmatic rod- and ring-shaped pattern which is apparently associated to HCV infection. There are ongoing studies to establish its immunological identity (Figure 2).

As they are not definitely characterized, these two new patterns have been considered preliminary and the 3rd Consensus recommended that both patterns have to be completely characterized and presented in the next meeting.

Genetically modified cell-based substracts
The 3rd Consensus did not discuss any systematic study with genetically modified cell substract; this could be a possible topic for the next meetings.

QUALITY CONTROL

The Third Consensus promotes and recommends strategies for quality control. This recommendation aims at facing difficulties to assure test quality due to specialized trained professionals needs, heterogeneity of commercial kits and non-standardization of optical equipment at laboratories. Among institutional quality programs, the following programs were mentioned: College of American Pathologists (CAP) and educational program for ANA-IIF in HEp-2 at Controlab. Other programs and reagents for quality control were also mentioned, such as PCQAUTO by GMK Diagnósticos, Conexão HEp-2 by Hemagen Diagnósticos and the blade FITC-QC® by ALKA Tecnologia em Diagnósticos.

It was also recommended the titration of conjugate as a fundamental measure to adjust the amount of fluorochrome according to the lamp power, matching the different departments. This procedure should also be performed for every new kit in a different lot. This titration maintenance in kits from the same lot may be performed using low intensity controls. In this item, it is useful to use commercial slides with pre-calibrated

Figure 1. (A) Nuclear fine speckled tending to be homogeneous. Cells present nucleoplasm with finely speckled texture with homogeneous trend and stained metaphase plate in the same texture. This pattern should not be confused with homogeneus nuclear pattern and dense nuclear fine speckled pattern, respectively. In figures B and C may be observed Homogeneus nuclear pattern and dense nuclear fine speckled pattern, respectively.
microsphere for different fluorescence intensity and that may be used for training and internal calibration of reading.

In order to stimulate the achievement of authentic results, the 3rd Consensus recommends the laboratories to take part at quality control programs and systematically perform technical quality control. It is fundamental to remember that IIF reaction depends on five factors: Optical system (microscope), light power (20, 50 or 100W), conjugate concentration, control serum of minimum reactivity (1/80) and observer.

Conjugate concentration allows matching different optical systems, different power lights and observer’s reading. For example, if the light power is low, a more concentrate conjugate use is recommended in order to get the same fluorescence of a light with more power. In order to establish the ideal concentration of conjugate (conjugate’s titer), one should use titration technique in blocks where several dilutions of conjugate are crossed with several concentrations of a reference serum, searching the higher dilution of conjugate that is capable to reproduce nominal titer of reference serum.

This reference serum may be included with the kit and the laboratory will begin to be based on the optical, light and reader system according to patterns established by the manufacturer. This reference serum may be commercially acquired from quality control institutions or the laboratory will be able to send its serum to a laboratory of its reference and, then, with the results, start to consider this laboratory as reference. Once the first reference is done, the laboratory may store weekly aliquots of serum of titers established in this laboratory.

The laboratory should keep in its serum bank samples for controlling with minimum reactivity titer (1/80), to be diluted in 1/40, 1/80, 1/160, and 1/320. At each daily set, the laboratory should process the low control and consider this set valid if titer variation is more or less one dilution. If any control in conformity is seen, for example, if a sample with average titer of 1/80 is negative, this set should be considered invalid. Using the minimum reactivity control (1/80), a set of tests will only be considered valid after reading one titer at more or less 80. In case of a decrease over 1 titer, the system is probably unstable. It is recommended to first verify if there was any problem in the aliquot stored; in this case, repeat the test with the aliquot stored the week before. If in the end of repetition, the titer found was the expected, we may conclude that the control aliquot used was deteriorated. If the new aliquot also presented a titer decrease of more than one dilution, we should check the optical system (UV filter deterioration, buffered glycerin in the objective lens and lamp performance). If no change is found in these components and in the number of hours of the lamp use, the most probable cause is conjugate degradation; if so, conjugate should go through a new titration process, as described before.

Notes
1. It is recommended to perform conjugate control every 15 days.
2. When a new kit is opened, a new titration of conjugate should be performed.
3. Microscope’s objective lens and filters interfere in the definition of conjugate titer and should be periodically checked.
4. Additionally to checking the time of the lamp, it is necessary to check if the lamp is in the center. It can be performed by placing a white paper sheet on the microscope table and using the objective lens 10 to see if the lamp is in the center. If you notice any dark part of the field, adjust it by using the following bottoms: left-right center, up and down center, and lamp focus.

CLINICAL ASSOCIATIONS AND PATTERN DESCRIPTION

Members of the 3rd Consensus proceeded to a wide discussion for validation and reevaluation of clinical and immunological associations about ANA-IIF patterns in HEp-2. Recommendations are listed in Table 1.

Most of the associations above had been accepted by general agreement by the Consensus members. In rare non-unanimous cases, the majority opinion prevailed.
Such initiative shows the intense activity in auto-antibodies research, and particularly, in antinuclear antibody, in Brazil. We should emphasize that this activity has been providing a progressive and remarkable development in our scientific and professional community, establishing an independent national position about the way to perform and interpret assay to screen autoantibodies using HEp-2 cells. The physicians and consequently their patients has also benefited of this laboratory test. Finally, it is necessary to explain that this is a continuous and progressive process and it depends on the interaction of the whole community involved in several steps of this process.

### ACKNOWLEDGEMENTS
- Brazilian Society of Rheumatology (BSR)
- Brazilian Society of Clinical Pathology and Laboratorial Medicine (BSCP)
- Brazilian Society of Clinical Analysis (BSCA)
- Local Advisory Board of Biomedicine 3th Region

#### Table 1
ANA pattern by IIF using HEp-2 substrate, description, main related autoantibodies and more frequent clinical associations

<table>
<thead>
<tr>
<th>Patterns</th>
<th>Description</th>
<th>Clinical relevance for autoantibodies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nuclear, type nuclear membrane</td>
<td>Pattern characterized by fluorescence in the whole nuclear membrane (it may be issued with additional information in continuous or speckled aspect): No fluorescence is seen in nucleolus and cytoplasm; dividing cell presents no fluorescence in all stages. Do not confuse with the old peripheral pattern seen in rat’s liver where double helix DNA was fixed to nuclear membrane protein, giving its characteristic aspect.</td>
<td>Antibody against nuclear envelope proteins. Primary biliary cirrhosis, autoimmune hepatitis, rarely associated to rheumatic diseases. Some forms of systemic lupus erythematosus and linear scleroderma, antiphospholipid syndrome. Such pattern may be observed in individuals without apparent evidence of autoimmunity, especially when in low titers. Anti-gp210 antibody is specific for primary biliary cirrhosis. Other autoantibodies associated to this pattern: anti-p62 (nucleoparin), anti-lamins A, B, and C, anti-LBP.</td>
</tr>
<tr>
<td>Homogeneous nuclear</td>
<td>Homogeneous and even staining of the nucleus It is not possible to distinguish the nucleolus and it is considered non reagent. Chromosome metaphase plate with intense staining, hyaline aspect, with homogeneous decoration of chromosomes, also positive in anaphase and telophase. Cytoplasm normally non fluorescent.</td>
<td>Anti-DNA double stranded antibody. Indication of systemic lupus erythematosus</td>
</tr>
<tr>
<td>Nuclear coarse speckled</td>
<td>Nucleoplasm with coarse speckles, heterogeneous in size and brightness, highlighting some bigger and brighter granules (1 to 6/nucleus) corresponding to Cajal body, rich in spliceosome ribonucleoproteins. Nucleolus, mitotic cells and cytoplasm are not stained.</td>
<td>Anti-Sm antibody. Indicative of systemic lupus erythematosus. Anti-RNP antibody. Mandatory criteria in diagnosis of mixed connective tissue disease, also present in systemic lupus erythematosus and systemic sclerosis.</td>
</tr>
<tr>
<td>Dense nuclear fine speckled</td>
<td>Nucleoplasm of a cell in interphase stage present as a peculiar speckle, with heterogeneous distribution, not stained nucleolus. Mitotic cells present an intense and rough speckled decoration of chromosomes in metaphase plate. Cytoplasm not stained.</td>
<td>Antiprotein p75 antibody (transcription cofactor) named LEDGF/p75, one of the most frequent patterns found in routine, which clinical correlation has not been completely established, and it is frequently found in individuals with no objective evidence of a systemic disease. Rarely found in rheumatic diseases, autoinmune diseases and specific and non specific inflammatory processes. There are reports in literature about finding such pattern in patients with interstitial cystitis, atopic dermatitis, psoriasis and asthma.</td>
</tr>
<tr>
<td>Speckled nuclear with isolated dots</td>
<td>Nucleoplasm presents isolated fluorescent dots (additional information: the number of dots ≥10 or &lt; 10 dots per nucleus). Nucleolus, mitotic cells and cytoplasm are not stained.</td>
<td>Anti-p80 coilin antibody. No clinical association defined. Anti-Sp100 – anti-p95 antibody. Described especially in primary biliary cirrhosis.</td>
</tr>
</tbody>
</table>
### Nuclear speckled centromere

- **Description:** 46 bright speckles spread over the nucleus of interphase cells. Nucleolus and cytoplasm not stained. Mitotic cells present dots concentration in metaphase plate.
- **Antibody:** Anticentromere antibody (CENP-A, CENP-B and CENP-C proteins). CREST - systemic sclerosis (calcinosi, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly and telangectasia), primary biliary cirrhosis, and Sjögren's syndrome. Rarely observed in other autoimmune diseases. It may precede CREST for many years.17,18

### Pleomorphic nuclear speckled

- **Description:** Nucleoplasm totally not stained in G1 cell interphase, becoming speckled with grains ranging from coarse, fine to dense fine, at the time the cell passes to phases S and G2. Nucleolus and cytoplasm not stained.
- **Antibody:** Proliferating cell nuclear antigen (anti-PCNA). Specifically found in patients with systemic lupus erythematosus.19

### Homogenous nucleolar

- **Description:** Evenly bright fluorescence nucleolus, mitotic cells and cytoplasm not stained.
- **Antibody:** Antihistone anti-To/Th. Occurs in systemic sclerosis.20

### Clumpy nucleolar

- **Description:** Nucleolus presents tight clusters of fluorescent granules (such as a bunch of grapes). Cytoplasm and nucleus not stained, mitotic cell is amorphous, with soft color around metaphase plate chromosomes.
- **Antibody:** Antifibrillarin antibody (U3-nRNP). Related to systemic sclerosis, especially with severe visceral damage, such as pulmonary hypertension.21

### Speckled nucleolar

- **Description:** Fine and discrete speckles in the nucleolus; 5-10 different and brilliant dots along chromosomal metaphase plate. Cytoplasm and nucleus not stained.
- **Antibody:** Anti-NOR 90 antibody. Initially described in systemic sclerosis, Today described in other autoimmune diseases, however without clinical relevance defined.21

### Linear cytoplasmatic fibrilar

- **Description:** Stressed fibers forming cytoskeleton decorated, crossing the whole extension of the cell, not respecting nuclear limits. Nucleus and nucleolus not stained.
- **Antibody:** Anti-actin antibody. Found in liver diseases: autoimmune hepatitis, cirrhosis.

### Filamentar cytoplasmatic fibrilar

- **Description:** Decoration with filaments with unipolar or bipolar accentuation related to nuclear membrane. Nucleus and nucleolus not stained.
- **Antibody:** Anti-vimentin and anti-keratin antibody. Anti-keratin antibody is the most important antibody in alcohol-related hepatic disease. Described in several inflammatory and infectious diseases. When in low or moderate titers, may have no clinical relevance.24

### Segmentary cytoplasmatic fibrilar

- **Description:** Only short stressed fiber segments are fluorescent. Nucleus and nucleolus not stained. In mitotic cells, we can eventually observe multiple fluorescent grains corresponding to globular form of cytoplasm protein.
- **Antibody:** Anti-alpha-actinin, anti-vinculin and anti-tropomyosin. Antibodies found in myasthenia gravis, Crohn's disease and ulcerative colitis. When in low or moderate titers, may have no clinical relevance.24

### Polar speckled cytoplasmatic

- **Description:** This is also a mandatory report, because it makes evident Golgi apparatus. Decoration is only cytoplasmatic in grouped dots in perinuclear situation on one pole of the nucleus. Nucleolus, mitotic cells and nucleus are not stained.
- **Antibody:** Anti-golgin antibody (Golgi apparatus cistern). Rare in systemic lupus erythematosus, primary Sjögren syndrome and other systemic autoimmune diseases. Reported in idiopathic cerebellar ataxia, paraneoplastic cerebellar degeneration and viral infection by Epstein Barr virus (EBV) and human immunodeficiency virus (HIV). When in low or moderate titers, may have no clinical relevance.25,26

### Speckled cytoplasmatic with isolated dots

- **Description:** Defined dots with variable number for the whole extension of cytoplasm. Nucleolus, mitotic cells and nucleus are not stained.
- **Antibody:** Anti-EEA1 antibody and anti-phosphatidylserine. No clinical associations well defined.
- **Antibody:** Anti-GWB antibody. Related to primary Sjögren syndrome, although also observed in several other clinical conditions.27
<table>
<thead>
<tr>
<th>Nucleolar to homogeneous cytoplasmatic mixed, type fine dense and nuclear fine speckled</th>
<th>Anti-PL7/PL12 antibody. This pattern may be rarely associated with antibodies found in polymyositis.25</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fine speckled cytoplasmatic</td>
<td>Fine speckles covering the whole cytoplasm. Mitotic cells and nucleoli not stained.</td>
</tr>
<tr>
<td>Fine speckled cytoplasmatic</td>
<td>Histidil anti tRNA synthetase antibody (Jo1). Marker antibody of polymyositis in adults. Rarely described in dermatomyositis. Other anti tRNA synthetases antibodies may generate the same pattern.29</td>
</tr>
<tr>
<td>Reticular speckled cytoplasmatic</td>
<td>Large and irregular speckles concentrated in the perinuclear region and extended in lower density to the rest of the cytoplasm. Nucleolus, mitotic cells and nucleoli are not stained.</td>
</tr>
<tr>
<td>Mitotic apparatus type centriole</td>
<td>In interphase cells, fluorescence is confined to a single sphere close to the nucleus, dividing in two and migrating to the opposite pole of nucleus as the cell starts to split.</td>
</tr>
<tr>
<td>Mitotic apparatus type intercellular bridge</td>
<td>Antigen forming the union between mother/daughter cells in the end of telophase. They may be observed with intense fluorescence in cytoplasmatic tip that will suffer cleavage in the end of cell division.</td>
</tr>
<tr>
<td>Mitotic apparatus type mitotic spindle (NuMa-2)</td>
<td>Interphase cells showed no nuclear or cytoplasmic staining, but mitotic cells had brightly stained poles and spindles. At telophase, staining shifted to the midbody and the intercellular bridge.</td>
</tr>
<tr>
<td>Mixed, Nuclear fine speckled type with fluorescence in Mitotic apparatus</td>
<td>Cells in interphase present a stained nucleus with a very fine speckled, generally, in high titer. Miotic cells in metaphase and anaphase present well defined and delicate location of perinuclear region and proximal parts of mitotic spindle. In telophase, the staining shifted from the centrosomes to the reforming nuclei and no stain in intercellular bridge.</td>
</tr>
<tr>
<td>Mixed, type homogeneous nucleolar and coarse speckled</td>
<td>Interphase cells present a stained nucleus with a coarse speckled and homogeneously reddish nucleolus. In metaphase, there is stain around metaphase plate.</td>
</tr>
<tr>
<td>Mixed, type fine nuclear and nucleolar fine speckled with stained metaphase plate</td>
<td>Interphase cells present a stained nucleus with a fine speckled form and nucleoli is also highlighted with fine speckled pattern. In metaphase, metaphase plate presents fine speckled pattern.</td>
</tr>
<tr>
<td>Mixed, type speckled nucleolar and nuclear fine speckled</td>
<td>Interphase cells present a stained nucleus with a fine speckled form and nucleoli is also highlighted with fine speckled pattern (individual dots). Cytoplasm is not stained. In metaphase, 5 to 10 isolated bright dots are seen in metaphase plate, corresponding to nucleolar organizing regions (NOR).</td>
</tr>
<tr>
<td>Mixed, type fine dense speckled cytoplasmatic nucleolar to homogeneous nucleolar</td>
<td>Nucleus is totally not stained and nucleoli is poorly stained. Cytoplasm presents strong stain with very fine and very dense speckled, almost homogeneous. Mitotic cells are not stained.</td>
</tr>
<tr>
<td>Anti-DNA Topoisomerase I antibody (Scl-70). Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-Ku antibody. Marker of polymyositis and systemic sclerosis overlap. May occur in systemic lupus erythematosus and scleroderma.21</td>
<td></td>
</tr>
<tr>
<td>Anti-DNA Topoisomerase I antibody (Scl-70). Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. This pattern may be rarely associated with antibodies found in polymyositis.25</td>
<td></td>
</tr>
<tr>
<td>Anti-alpha-enolase antibody. In low titers, there is no clinical association. In high titers, it may be associated with systemic sclerosis.</td>
<td></td>
</tr>
<tr>
<td>Anti-alpha-enolase antibody. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titers.22</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titers.22</td>
<td></td>
</tr>
<tr>
<td>Anti-Ku antibody. Marker of polymyositis and systemic sclerosis overlap. May occur in systemic lupus erythematosus and scleroderma.21</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-DNA Topoisomerase I antibody (Scl-70). Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
<tr>
<td>Anti-PL7/PL12 antibody. Associated with systemic lupus erythematosus and Mixed Connective Tissue Disease. Other not well defined antibodies may generate the same pattern. Associated with several auto immune conditions with low specificity, with clinical relevance only in high titer.22</td>
<td></td>
</tr>
</tbody>
</table>
REFERENCES


